
AbbVie (ABBV) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
13.3B
Gross Profit
9.3B
70.01%
Operating Income
4.0B
29.84%
Net Income
1.3B
9.66%
EPS (Diluted)
$0.72
Balance Sheet Metrics
Total Assets
136.2B
Total Liabilities
134.7B
Shareholders Equity
1.5B
Debt to Equity
92.14
Cash Flow Metrics
Operating Cash Flow
2.3B
Free Cash Flow
1.4B
Revenue & Profitability Trend
AbbVie Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 56.3B | 54.3B | 58.1B | 56.2B | 45.8B |
Cost of Goods Sold | 16.9B | 20.4B | 17.4B | 17.4B | 15.4B |
Gross Profit | 39.4B | 33.9B | 40.6B | 38.8B | 30.4B |
Gross Margin % | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% |
Operating Expenses | |||||
Research & Development | 12.8B | 8.5B | 7.2B | 8.0B | 7.8B |
Selling, General & Administrative | 14.8B | 12.9B | 15.3B | 12.3B | 11.3B |
Other Operating Expenses | -7.0M | -179.0M | 56.0M | 432.0M | - |
Total Operating Expenses | 27.5B | 21.1B | 22.5B | 20.8B | 19.1B |
Operating Income | 11.9B | 12.8B | 18.1B | 17.9B | 11.4B |
Operating Margin % | 21.1% | 23.5% | 31.2% | 31.9% | 24.8% |
Non-Operating Items | |||||
Interest Income | 648.0M | 540.0M | 186.0M | 39.0M | 174.0M |
Interest Expense | 2.8B | 2.2B | 2.2B | 2.4B | 2.5B |
Other Non-Operating Income | -6.0B | -4.8B | -2.6B | -2.6B | -5.7B |
Pre-tax Income | 3.7B | 6.2B | 13.5B | 13.0B | 3.4B |
Income Tax | -570.0M | 1.4B | 1.6B | 1.4B | -1.2B |
Effective Tax Rate % | -15.3% | 22.0% | 12.1% | 11.1% | -36.0% |
Net Income | 4.3B | 4.9B | 11.8B | 11.5B | 4.6B |
Net Margin % | 7.6% | 9.0% | 20.4% | 20.6% | 10.1% |
Key Metrics | |||||
EBITDA | 17.7B | 17.3B | 24.3B | 24.0B | 12.4B |
EPS (Basic) | $2.40 | $2.73 | $6.69 | $6.53 | $2.62 |
EPS (Diluted) | $2.39 | $2.72 | $6.63 | $6.45 | $2.62 |
Basic Shares Outstanding | 1769000000 | 1768000000 | 1769181294 | 1768337696 | 1765132819 |
Diluted Shares Outstanding | 1769000000 | 1768000000 | 1769181294 | 1768337696 | 1765132819 |
Income Statement Trend
AbbVie Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.5B | 12.8B | 9.2B | 9.7B | 8.4B |
Short-term Investments | 31.0M | 2.0M | 28.0M | 84.0M | 30.0M |
Accounts Receivable | 10.9B | 11.2B | 11.3B | 10.0B | 8.8B |
Inventory | 4.2B | 4.1B | 3.6B | 3.1B | 3.3B |
Other Current Assets | 4.9B | 4.9B | 4.4B | 5.0B | - |
Total Current Assets | 25.6B | 33.0B | 28.5B | 27.9B | 24.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Goodwill | 130.0B | 120.2B | 131.8B | 140.7B | 149.1B |
Intangible Assets | 60.1B | 55.6B | 67.4B | 76.0B | 82.9B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 9.1B | 8.5B | 5.6B | 4.9B | 4.9B |
Total Non-Current Assets | 109.6B | 101.7B | 110.3B | 118.6B | 126.4B |
Total Assets | 135.2B | 134.7B | 138.8B | 146.5B | 150.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.9B | 3.7B | 2.9B | 2.9B | 2.3B |
Short-term Debt | 6.8B | 7.2B | 4.1B | 12.5B | 8.5B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 38.7B | 37.8B | 29.5B | 35.2B | 28.7B |
Non-Current Liabilities | |||||
Long-term Debt | 60.3B | 52.2B | 59.1B | 64.2B | 77.6B |
Deferred Tax Liabilities | 2.6B | 2.0B | 2.2B | 3.0B | 3.6B |
Other Non-Current Liabilities | 27.6B | 28.6B | 26.0B | 22.1B | 20.3B |
Total Non-Current Liabilities | 93.0B | 86.5B | 92.0B | 95.9B | 108.8B |
Total Liabilities | 131.8B | 124.3B | 121.5B | 131.1B | 137.5B |
Equity | |||||
Common Stock | 18.0M | 18.0M | 18.0M | 18.0M | 18.0M |
Retained Earnings | -7.9B | -1.0B | 4.8B | 3.1B | 1.1B |
Treasury Stock | 8.2B | 6.5B | 4.6B | 3.1B | 2.3B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.4B | 10.4B | 17.3B | 15.4B | 13.1B |
Key Metrics | |||||
Total Debt | 67.1B | 59.4B | 63.3B | 76.7B | 86.1B |
Working Capital | -13.2B | -4.8B | -1.1B | -7.3B | -4.5B |
Balance Sheet Composition
AbbVie Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 4.3B | 4.9B | 11.8B | 11.5B | 4.6B |
Depreciation & Amortization | 8.4B | 8.7B | 8.5B | 8.5B | 6.5B |
Stock-Based Compensation | 911.0M | 747.0M | 671.0M | 692.0M | 753.0M |
Working Capital Changes | -3.1B | 3.0B | 170.0M | -1.0B | -28.0M |
Operating Cash Flow | 13.5B | 19.2B | 22.4B | 22.8B | 17.5B |
Investing Activities | |||||
Capital Expenditures | -974.0M | -777.0M | -695.0M | -787.0M | -798.0M |
Acquisitions | -20.5B | -1.2B | -794.0M | -1.9B | -39.6B |
Investment Purchases | -73.0M | -77.0M | -1.4B | -119.0M | -61.0M |
Investment Sales | 555.0M | 55.0M | 1.5B | 98.0M | 1.5B |
Investing Cash Flow | -20.8B | -2.0B | -623.0M | -2.3B | -37.6B |
Financing Activities | |||||
Share Repurchases | -1.7B | -2.0B | -1.5B | -934.0M | -978.0M |
Dividends Paid | -11.0B | -10.5B | -10.0B | -9.3B | -7.7B |
Debt Issuance | 17.0B | 0 | 2.0B | 1.0B | 3.0B |
Debt Repayment | -14.6B | -4.1B | -14.4B | -9.4B | -5.7B |
Financing Cash Flow | -10.4B | -17.4B | -25.1B | -19.3B | -11.7B |
Free Cash Flow | 17.8B | 22.1B | 24.2B | 22.0B | 16.8B |
Net Change in Cash | -17.8B | -170.0M | -3.3B | 1.2B | -31.8B |
Cash Flow Trend
AbbVie Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
97.94
Forward P/E
17.04
Price to Book
-2,641.62
Price to Sales
6.26
PEG Ratio
-3.02
Profitability Ratios
Profit Margin
6.45%
Operating Margin
37.52%
Return on Equity
112.85%
Return on Assets
8.87%
Financial Health
Current Ratio
0.74
Debt to Equity
-511.49
Beta
0.50
Per Share Data
EPS (TTM)
$2.11
Book Value per Share
$-0.10
Revenue per Share
$32.98
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
abbv | 365.1B | 97.94 | -2,641.62 | 112.85% | 6.45% | -511.49 |
Eli Lilly and | 618.5B | 45.00 | 33.86 | 86.29% | 25.91% | 217.89 |
Johnson & Johnson | 428.2B | 19.06 | 5.45 | 30.21% | 25.00% | 64.69 |
Merck & Co | 212.1B | 13.09 | 4.34 | 35.42% | 25.79% | 72.16 |
Amgen | 159.6B | 24.22 | 21.48 | 99.14% | 18.96% | 756.65 |
Gilead Sciences | 146.4B | 23.41 | 7.45 | 33.40% | 21.87% | 127.34 |
Financial data is updated regularly. All figures are in the company's reporting currency.